| 1 |
NCT03665025 |
Not yet recruiting |
Immediate Implant Placement With Immediate Professionalization in Aesthetic Area |
|
- Other: immediate implant using mixed allograft and xenograft
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Crestal bone loss
- Patient satisfaction
|
2 |
All |
20 Years to 60 Years (Adult) |
NCT03665025 |
14422017463550 |
|
January 1, 2019 |
January 1, 2019 |
January 1, 2019 |
September 11, 2018 |
September 11, 2018 |
|
- Mohammed
Kuwait, Q8, Kuwait
|
|
| 2 |
NCT03656965 |
Active, not recruiting |
EBV Positive Nasopharyngeal Carcinoma Treated With Concurrent Chemo-radiotherapy With or Without Anti-Viral Drug |
- Drug Use for Unapproved Schedule
|
- Drug: Acyclovir 800 MG
- Combination Product: Radiotherapy and chemotherapy
|
Interventional
|
Phase 3 |
- Kuwait Cancer Control Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with Eliminated EBV titre as assessed by quantitative PCR-DNA in patients with NPC.
|
50 |
All |
Child, Adult, Older Adult |
NCT03656965 |
RODKCCC |
|
May 1, 2018 |
May 2021 |
May 2021 |
September 3, 2018 |
September 3, 2018 |
|
- Kuwait Cancer Control Center
Kuwait, Kuwait
|
|
| 3 |
NCT03618147 |
Recruiting |
Primary Immunodeficiency in Kuwait |
- Primary Immune Deficiency Disorder
|
|
Observational
|
|
- Kuwait Society for Allergy and Clinical Immunology
|
Other |
- Observational Model: Cohort
- Time Perspective: Other
|
- Number of primary immunodeficiency disorders patients in Kuwait by using recruitment form which includes clinical and laboratory data
|
350 |
All |
Child, Adult, Older Adult |
NCT03618147 |
IIR - K W T - 0 0 2 0 7 1 |
|
July 16, 2018 |
July 15, 2019 |
July 15, 2019 |
August 7, 2018 |
August 7, 2018 |
|
- Pediatric Deprtmemt, Alsabah hospital
Kuwait, Kuwait
|
|
| 4 |
NCT03532737 |
Recruiting |
Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer |
- Locally Advanced Head and Neck Cancer
|
|
Interventional
|
Phase 2 |
- Kuwait Cancer Control Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Limiting Toxicity (DLT)
- Response Rate
- Locoregional control rates
- (and 2 more...)
|
50 |
All |
16 Years and older (Child, Adult, Older Adult) |
NCT03532737 |
HNIT 01 |
|
October 7, 2018 |
September 30, 2021 |
October 31, 2022 |
May 22, 2018 |
October 17, 2018 |
|
- Kuwait Cancer Control Center
Kuwait, Kuwait
|
|
| 5 |
NCT03358394 |
Active, not recruiting |
Mindfulness-based Arabic Guided Self-help for Parents of Children With Type 1 Diabetes |
- Diabetes Mellitus, Type 1
|
- Behavioral: A human-interventional study
|
Interventional
|
Not Applicable |
- SHAHAH ALTAMMAR
- University of Sheffield
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Other
|
- Generalized Anxiety Disorder Scale (GAD-7)
- The Patient Health Questionnaire (PHQ-9).
- Mindfulness
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03358394 |
Reference Number 016511 |
|
October 26, 2017 |
February 26, 2018 |
May 16, 2018 |
November 30, 2017 |
December 6, 2017 |
|
- Shahah Altammar
Kuwait, Kuwait
|
|
| 6 |
NCT03347916 |
Recruiting |
Gabapentin Oral Solution in Decreasing Desflurane Associated Emergence Agitation |
- Emergence Agitation After Desflurane Anesthesia
|
- Drug: Strawberry juice as (placebo)
- Drug: Gabapentin Oral Solution [Neurontin]
|
Interventional
|
Not Applicable |
- Kuwait Specialized Eye Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- emergence agitation incidence and scores
- duration of emergence
|
75 |
All |
2 Years to 6 Years (Child) |
NCT03347916 |
kuwaiteyecenter01 |
|
January 5, 2017 |
November 25, 2017 |
November 30, 2017 |
November 20, 2017 |
November 21, 2017 |
|
- Kuwait Specialized Eye Center
Kuwait, Kuwait
|
|
| 7 |
NCT03326037 |
Recruiting |
Study of The Association of Mutations in The NPHS2 Gene and Nephrotic Syndrome in Children and Adults in Middle East |
|
- Genetic: Genotyping of the NPHS2 variant rs61747728
|
Observational
|
|
- AHMED ABDULQADER HAMMOUDA ABOU SHALL
- Kuwait University
- Assiut University
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of participants achieving NPHS2 gene mutations (frequency of p.R229Q polymorphic site) in patients with steroid-resistant nephrotic syndrome in comparison with steroid - sensitive nephrotic syndrome
|
150 |
All |
2 Years to 50 Years (Child, Adult) |
NCT03326037 |
MG03/15 |
|
October 2016 |
October 2018 |
August 2019 |
October 30, 2017 |
October 30, 2017 |
|
- Faculty of Medicine-Pathology Department
Ḩawallī, Kuwait
|
|
| 8 |
NCT03236779 |
Recruiting |
A Comparative Study of Two Dry Needling Interventions for Plantar Heel Pain |
- Plantar Fascitis
- Myofacial Pain Syndromes
- Trigger Point Pain, Myofascial
|
|
Interventional
|
Not Applicable |
- Universidad de Zaragoza
- Universidad San Jorge
- Ministry of Health, Kuwait
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Foot Health status questioner (FHSQ)
- VAS
- The Quality of Life (QoL) will be assessed with the EuroQoL-5 dimensions (EQ-5D
|
94 |
All |
21 Years to 60 Years (Adult) |
NCT03236779 |
ALBOLOUSHI |
|
January 14, 2018 |
February 25, 2019 |
May 30, 2019 |
August 2, 2017 |
April 5, 2018 |
|
- Physical Medicine and rehabilitation Kuwait
Kuwait, Kuwait
|
|
| 9 |
NCT03066284 |
Recruiting |
A Qualitative Study on CSII in Children and Adolescents Having Type 1 Diabetes |
|
|
Observational
|
|
- Dasman Diabetes Institute
|
Other |
- Observational Model: Case-Only
- Time Perspective: Other
|
- Impact of IPT on QoL of children and adolescents from their perspective and their parents' perspective
|
20 |
All |
4 Years to 18 Years (Child, Adult) |
NCT03066284 |
RA 2016-006 |
|
March 14, 2016 |
March 13, 2017 |
March 13, 2019 |
February 28, 2017 |
February 28, 2017 |
|
- Dasman Diabetes Institute
Sharq, Kuwait City, Kuwait
|
|
| 10 |
NCT02791867 |
Terminated |
Comparison of Laboratory Changes, Food Intake and Metabolic Profile in Patients With Obesity and Type2 Diabetes Mellitus: Before, During and After Taking AphoelineBrake |
- Diabetes Mellitus, Type 2
|
|
Interventional
|
Phase 1
Phase 2 |
- Dasman Diabetes Institute
- University at Buffalo
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Basic Science
|
- Reduction in Insulin Resistance measured by HOMA-IR
- Reduction in glycated Haemoglobin measured: HBA1c
- Reduction in serum triglyceride level (mmol/l)
|
48 |
All |
21 Years and older (Adult, Older Adult) |
NCT02791867 |
RA 2014-019 |
|
December 2014 |
December 2018 |
December 2018 |
June 7, 2016 |
August 2, 2017 |
|
- Dasman DIabetes Institute
Kuwait, Kuwait
|
|
| 11 |
NCT02713789 |
Unknown † |
Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene for ED |
|
- Drug: hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection)
- Drug: Placebo (PBS-20% sucrose)
|
Interventional
|
Phase 2 |
- Ion Channel Innovations
- Dasman Diabetes Institute
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
|
- Efficacy
- Physical examination
- Clinical laboratory tests
- EKG
|
35 |
Male |
18 Years to 80 Years (Adult, Older Adult) |
NCT02713789 |
ION04-ED |
|
April 2015 |
June 2016 |
December 2016 |
March 21, 2016 |
March 21, 2016 |
|
- Dasman Diabetes Institute
Kuwait city, Dasman, Kuwait
|
|
| 12 |
NCT02661906 |
Completed |
A Pilot Study on Effect of SKY on Psychosocial Parameters of Type 2 Diabetic Patients After a 6 Days Intervention |
- Diabetes Mellitus, Non-Insulin-Dependent
|
|
Interventional
|
Not Applicable |
- Dasman Diabetes Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Improvement in quality of life
- Improvement in HbA1c
- Improvement in BMI
- Improvement in lipid profile
|
24 |
All |
30 Years to 65 Years (Adult, Older Adult) |
NCT02661906 |
RA 2014-028 |
|
August 2016 |
December 2017 |
February 2018 |
January 25, 2016 |
February 8, 2018 |
|
- Dasman Diabetes Institute
Kuwait, Kuwait
|
|
| 13 |
NCT02444182 |
Completed
Has Results |
Effects of Probiotics on Oral Health |
- Periodontal Health
- Dental Plaque Accumulation
|
- Dietary Supplement: Probiotics
- Dietary Supplement: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- Kuwait University
- University of Turku
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Gingival Health
- Plaque Index
|
108 |
Male |
13 Years to 15 Years (Child) |
NCT02444182 |
DD04/13 |
|
December 2014 |
May 2015 |
June 2015 |
May 14, 2015 |
March 14, 2016 |
March 14, 2016 |
- Abdullah Alwaheeb intermediate School
Kuwait, Kuwait
|
|
| 14 |
NCT02024139 |
Completed |
Efficacy of Chewing Sugarless Gum for Reduction of Orthodontic Appliance Pain |
- Pain Associated With Fixed Orthodontic Treatment
|
- Other: Chewing Sugarless Gum
- Other: Using Mouthwash
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Pain scale reading
- Patient subjective assessment of pain experience
|
36 |
All |
10 Years to 35 Years (Child, Adult) |
NCT02024139 |
DD01/13 |
|
January 2014 |
April 2016 |
April 2016 |
December 31, 2013 |
April 12, 2016 |
|
- Bneid Algar Dental Speciality Center
Kuwait City, Kuwait
|
|
| 15 |
NCT01980459 |
Completed |
Magnesium Treatment of Inflammation in Disorders of Glucose Homeostasis |
- Non-Insulin Dependent Diabetes Mellitus
|
- Dietary Supplement: magnesium lactate
|
Interventional
|
Phase 1 |
- George Washington University
- Nadia Zghoul, PhD, Dept of Clinical Research
- Dasman Diabetes Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- The magnesium cellular levels will provide a stronger correlation with antiinflammatory indicators compared to the circulating serum levels of magnesium.
- Magnesium supplementation will lower parameters of inflammation in hypomagnesemic diabetic patients.
|
47 |
All |
20 Years to 70 Years (Adult, Older Adult) |
NCT01980459 |
IRB#071317 |
MagInGlu |
October 2013 |
July 2016 |
July 2016 |
November 11, 2013 |
November 30, 2016 |
|
- The Dasman Diabetes Institute
Kuwait City, Kuwait
|
|
| 16 |
NCT01528969 |
Completed
Has Results |
Effect of Xylitol on Oral Microbiota in Children |
|
- Dietary Supplement: xylitol
- Dietary Supplement: sorbitol
|
Interventional
|
Phase 1
Phase 2 |
- Kuwait University
- University of Turku
- University of Michigan
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- MS Counts of Stimulated Saliva
- The Changes in the Counts of the 14 Other Bacterial Species
|
122 |
Male |
11 Years to 14 Years (Child) |
NCT01528969 |
DD02/10
KU-DD02/10 |
|
March 2012 |
April 2012 |
May 2012 |
February 8, 2012 |
August 10, 2015 |
August 10, 2015 |
- Faculty of Dentistry, Kuwait University
Kuwait, Kuwait
|
|
| 17 |
NCT01509443 |
Unknown † |
Breathing & Mild Physical Exercise Therapy for Asthma |
|
|
Interventional
|
Not Applicable |
- Dasman Diabetes Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Post-bronchodilator Forced Expired Volume in one second (FEV1)
- Improvement in other pulmonary functions as well as quality of life assessment
- Change in Fraction of exhaled nitric oxide (FeNO)
- Change in Immunological Markers
|
200 |
All |
18 Years and older (Adult, Older Adult) |
NCT01509443 |
RA-2011-015 |
|
April 2012 |
December 2017 |
December 2017 |
January 13, 2012 |
February 11, 2016 |
|
- Dasman Diabetes Institute
Kuwait, Kuwait
|
|
| 18 |
NCT01438866 |
Completed |
Use of Fissure Sealants on Primary Molars |
|
- Other: Fissure sealant
- Other: Fissure sealants and fluoride varnish
|
Interventional
|
Phase 4 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of healthy occlusal tooth surfaces of primary molars
- Number of healthy occlusal tooth surfaces after application of fissure sealants versus fluoride varnish
|
148 |
All |
42 Months to 52 Months (Child) |
NCT01438866 |
DD03/10 |
|
October 2011 |
March 2013 |
April 2013 |
September 22, 2011 |
March 18, 2014 |
|
- Kindergarten
Kuwait, Hawally, Kuwait
|
|
| 19 |
NCT01165489 |
Completed |
Discovering Laryngomalacia |
|
|
Observational
|
|
- Boushahri Clinic Medical Center
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
|
1500 |
All |
up to 12 Months (Child) |
NCT01165489 |
Boushahri Medical Center |
|
January 2007 |
July 2009 |
September 2009 |
July 20, 2010 |
July 20, 2010 |
|
- Boushahri Clinic Medical Center
Kuwait, Kuwait
|
|
| 20 |
NCT01097759 |
Completed |
LigaSure Hemorrhoidectomy Versus Stapled Hemorrhoidopexy |
|
|
Observational
|
|
- Kuwait Oil Company Ahmadi Hospital
- Netherlands: Ministry of Health, Welfare and Sports
|
Other |
- Time Perspective: Prospective
|
- Assessment of postoperative pain
- Assessment of postoperative complications
|
115 |
All |
18 Years and older (Adult, Older Adult) |
NCT01097759 |
58061302393 |
|
January 2006 |
July 2007 |
July 2008 |
April 2, 2010 |
April 2, 2010 |
|
- Ahmadi Hospital
Ahmadi, Kuwait
|
|
| 21 |
NCT01042223 |
Completed |
Laryngomalacia Exposed |
|
|
Observational
|
|
- Boushahri Clinic Medical Center
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
|
1500 |
All |
up to 2 Years (Child) |
NCT01042223 |
Boushahri Clinic |
|
January 2006 |
July 2008 |
September 2008 |
January 5, 2010 |
July 19, 2010 |
|
- Boushahri Clinic Medical Center
Kuwait, P.O.Box :698 Salmiya, Kuwait
|
|
| 22 |
NCT00972764 |
Completed |
Laryngomalacia No Longer An Ambiguity |
|
|
Observational
|
|
- Boushahri Clinic Medical Center
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
|
1500 |
All |
up to 2 Years (Child) |
NCT00972764 |
461956 (BoushahriCMC) |
|
January 2006 |
July 2008 |
September 2008 |
September 7, 2009 |
September 7, 2009 |
|
- Boushahri Clinic Medical Center
Kuwait, P.O.Box :698 Salmiya, Kuwait
|
|
| 23 |
NCT03397225 |
Completed |
A Lifestyle Intervention for Type 2 Diabetes Patients in Kuwait and Its Impact on Glycaemic Control |
- Diabetes Mellitus, Noninsulin-Dependent
- Diabetes, Type 2
|
- Behavioral: Lifestyle intervention
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
40 |
Male |
30 Years to 65 Years (Adult, Older Adult) |
NCT03397225 |
13/53 |
|
November 15, 2013 |
January 29, 2015 |
February 29, 2016 |
January 11, 2018 |
January 16, 2018 |
|
- Al-Rehab polyclinic
Kuwait, Farwaniyah, Kuwait - University of Reading
Reading, Berkshire, United Kingdom
|
|
| 24 |
NCT03396263 |
Recruiting |
Online vs. Face-to-face Nutritional Advice in Kuwait (EatWellQ8) |
- Dietary Modification
- Dietary Habits
|
- Behavioral: Non-personalised advice
- Behavioral: Online personalised advice
- Behavioral: Face-to-face personalised advice
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Dietary change
- Weight
- Physical activity
|
300 |
All |
21 Years and older (Adult, Older Adult) |
NCT03396263 |
13/17b |
EatWellQ8 |
December 24, 2017 |
October 1, 2018 |
December 24, 2018 |
January 10, 2018 |
January 17, 2018 |
|
- Dasman Diabetes Institute
Kuwait City, Kuwait - University of Reading
Reading, Berkshire, United Kingdom
|
|
| 25 |
NCT01081626 |
Completed
Has Results |
Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction |
|
- Drug: Recombinant FSH (follitropin alpha)
|
Interventional
|
Phase 4 |
- Merck KGaA
- Merck Serono Middle East FZ-LLC, United Arab Emirates, an affiliate of Merck KGaA, Darmstadt, Germany
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With a Mono-follicular Development
- Number of Participants With Multi-follicular Development
- Number of Participants With Adverse Events (AEs)
- (and 8 more...)
|
310 |
Female |
18 Years to 37 Years (Adult) |
NCT01081626 |
EMR 700623-501 |
|
March 2009 |
March 2011 |
March 2011 |
March 5, 2010 |
February 13, 2014 |
November 7, 2012 |
- New Mowasat Hospital
Salmiya, P.O.Box 6661, Kuwait - Mount Lebanon Hospital
Hazmieh, P.O.Box 470, Lebanon - King Abdel Aziz University Hospital
Jeddah, P.O.Box 80215, Saudi Arabia
|
|
| 26 |
NCT02798315 |
Completed |
Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of participants achieving sustained virological response 12 weeks post-treatment (SVR12)
- The percentage of the direct-acting antiviral (DAA) dose taken in relation to the target dose of DAA.
- The percentage of the Ribavirin (RBV) dose taken in relation to the target dose of RBV
- (and 8 more...)
|
40 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT02798315 |
P15-699 |
|
May 25, 2016 |
June 12, 2017 |
June 12, 2017 |
June 14, 2016 |
June 21, 2017 |
|
- Adan Hospital /ID# 150776
Adan, Kuwait - Mubarak Hospital /ID# 150772
Hawalli, Kuwait - Mubarak Hospital /ID# 150773
Hawalli, Kuwait - (and 2 more...)
|
|
| 27 |
NCT02793180 |
Completed |
Documentation of Heart Failure in a Gulf Registry |
|
|
Observational
|
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Cross-Sectional
|
- Quantifying the causes of heart failure in the ambulatory patients in the outpatient setting
- Measure investigations that heart failure patients undergo
- Measuring patient functional status in heart failure patients
- (and 2 more...)
|
3680 |
All |
21 Years and older (Adult, Older Adult) |
NCT02793180 |
CLCZ696BKW01T |
DYSPNEA |
November 7, 2016 |
February 19, 2018 |
February 19, 2018 |
June 8, 2016 |
May 9, 2018 |
|
- Adan Hospital
Kuwait City, Kuwait - Amiri Hospital
Kuwait City, Kuwait - Chest Hospital
Kuwait City, Kuwait - (and 2 more...)
|
|
| 28 |
NCT03082976 |
Recruiting |
Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Prevalence of somatic BRCA mutations among ovarian cancer patients
- Associations or correspondence in prevalence between genetic alterations
- Describe epidemiological characteristics
- (and 2 more...)
|
120 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03082976 |
D133FR00118 |
PREDICT |
July 16, 2017 |
September 30, 2018 |
September 30, 2018 |
March 17, 2017 |
August 23, 2018 |
|
- Research Site
Kuwait, Kuwait - Research Site
Muscat, Oman - Research Site
Doha, Qatar - Research Site
Abu Dhabi, United Arab Emirates
|
|
| 29 |
NCT02805361 |
Completed |
Real World Assessment of Clinical Outcome Changes -Including Month of Ramadan-for Dapagliflozin in Management of Type II Diabetes Mellitus |
- Type II Diabetes Mellitus
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The mean change in HbAlc from mean baseline and at Month 12.
- Changes from baseline in Total body weight
- Changes from baseline in Total cholesterol
- (and 5 more...)
|
511 |
All |
18 Years and older (Adult, Older Adult) |
NCT02805361 |
D1690R00028 |
REWARD |
August 21, 2016 |
July 13, 2018 |
July 13, 2018 |
June 20, 2016 |
July 20, 2018 |
|
- Research Site
Kuwait City, Kuwait - Research Site
Abu Dhabi, United Arab Emirates - Research Site
Ajman, United Arab Emirates - Research Site
Dubai, United Arab Emirates
|
|
| 30 |
NCT00539448 |
Completed |
Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study |
- Diabetes Mellitus, Type 1
|
- Drug: insulin glargine
- Drug: insulin glulisine
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluating the Glycemic control of the regimen : Change in A1C levels
- Average daily dose : - For both insulin Glulisine & insulin Glargine. - FBG and PPBG if possible ?
|
98 |
All |
18 Years to 45 Years (Adult) |
NCT00539448 |
LANTU_L_01578 |
GLANS |
April 2007 |
December 2008 |
December 2008 |
October 4, 2007 |
September 25, 2009 |
|
- Sanofi-aventis administrative office
Manama, Bahrain - Sanofi-aventis administrative office
Kuwait City, Kuwait - Sanofi-Aventis Administrative Office
Doha, Qatar - Sanofi-aventis administrative office
Dubai, United Arab Emirates
|
|
| 31 |
NCT00477373 |
Completed |
Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study |
|
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The mean change in the Clinical Global Impressions Scale for Bipolar Disorder (CGI-BP)Severity score as well as the change in CGI-BP.
- Percentage of responders defined by a decrease of at least 50% of the CGI-BP.
- Time to achieve 50% and 30% improvement in the CGI-BP score.
- (and 4 more...)
|
70 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT00477373 |
DPKOT_L_01567 |
GEVANS |
December 2006 |
December 2007 |
|
May 23, 2007 |
December 19, 2008 |
|
- Sanofi-aventis administrative office
Bahrain, Bahrain - Sanofi-aventis administrative office
Kuwait, Kuwait - Sanofi-Aventis Administrative Office
Muscat, Oman - Sanofi-aventis administrative office
Qatar, Qatar
|
|
| 32 |
NCT01985607 |
Completed |
Efficacy of a New Thickened Extensively Hydrolyzed Formula |
- Protein Allergy
- Cow's Milk Protein Hypersensitivity
|
- Dietary Supplement: new extensively hydrolysed formula
- Dietary Supplement: Extensively hydrolysed formula
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Number of patient dropped out for intolerance
- Vandenplas' regurgitations score
- Cow's milk protein hypersensitivity score
- (and 2 more...)
|
72 |
All |
up to 6 Months (Child) |
NCT01985607 |
UP08-ALLAR |
ALLAR |
February 2011 |
July 2013 |
December 2013 |
November 15, 2013 |
March 24, 2015 |
|
- Universitair Ziekenhuis Brussel
Brussels, Belgium - Hippocration Hospital
Thessaloniki, Greece - Faculty of Medicine, Kuwait university
Safat, Kuwait - (and 2 more...)
|
|
| 33 |
NCT03703869 |
Recruiting
New |
Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost. |
|
- Drug: Insulin glargine (U300)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in HbA1c at month 6
- Change in HbA1c
- Change in fasting plasma glucose
- (and 5 more...)
|
4525 |
All |
18 Years and older (Adult, Older Adult) |
NCT03703869 |
OBS14708
U1111-1215-0174 |
ATOS |
March 6, 2018 |
June 2019 |
December 2019 |
October 12, 2018 |
October 12, 2018 |
|
- Investigational Site Number 1700001
Barranquilla, Colombia - Investigational Site Number 1700004
Bogota, Colombia - Investigational Site Number 1700010
Bogota, Colombia - (and 364 more...)
|
|
| 34 |
NCT01243138 |
Completed |
Africa and Middle East Cardiovascular Epidemiological Study |
- Obesity
- Smoking
- Dyslipidemia
- (and 2 more...)
|
|
Observational
|
|
|
Industry |
- Time Perspective: Cross-Sectional
|
- Prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension
- Compare the prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the urban and rural population.
- Compare the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the male and female population.
- (and 3 more...)
|
4386 |
All |
18 Years and older (Adult, Older Adult) |
NCT01243138 |
A2581186 |
ACE |
July 2011 |
April 2012 |
April 2012 |
November 18, 2010 |
June 27, 2012 |
|
- Pfizer Investigational Site
Alger, Algeria - Pfizer Investigational Site
Bejaja, Algeria - Pfizer Investigational Site
Djelfa, Algeria - (and 71 more...)
|
|
| 35 |
NCT01143818 |
Completed
Has Results |
ESPRIT Study in Hypogonadal Men |
|
- Drug: AndroGel (testosterone gel) 1%
|
Observational
|
|
|
Industry / Other |
- Observational Model: Ecologic or Community
- Time Perspective: Prospective
|
- Percent Change From Baseline to Month 6 in Aging Male Symptoms (AMS) in Mean Total Score
- Percent Change From Baseline to Month 6 in the International Index of Erectile Function (IIEF) Total Score
- Percent Change From Baseline to Month 6 in the Multidimensional Fatigue Inventory (MFI) Total Score
- Percent Change From Baseline to Month 6 in Body Mass Index (BMI)
|
1053 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01143818 |
S176.4.103 |
|
December 2007 |
August 2010 |
August 2010 |
June 14, 2010 |
October 17, 2011 |
September 26, 2011 |
- Site Ref # / Investigator 59749
Burnaby, British Columbia, Canada - Site Ref # / Investigator 59765
Coquitlam, British Columbia, Canada - Site Ref # / Investigator 59742
Kamloops, British Columbia, Canada - (and 328 more...)
|
|
| 36 |
NCT02153411 |
Completed |
Multicentric, Transversal, Descriptive, Epidemiological Study on the Management of Asthma in Asthmatic Middle East Adult Population |
|
|
Observational
|
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Asthma control
- general and sociodemographic patient's characteristics
- Identify predictive factors of asthma control,
- asthma control level
|
7294 |
All |
18 Years to 130 Years (Adult, Older Adult) |
NCT02153411 |
NIS-RME-XXX-2014/1 |
ESMAA |
June 2014 |
December 2015 |
December 2015 |
June 3, 2014 |
November 8, 2016 |
|
- Research Site
Ain Beida, Nis-rme-xxx-2014/1, Algeria - Research Site
Ain Naadja, Nis-rme-xxx-2014/1, Algeria - Research Site
Alger, Nis-rme-xxx-2014/1, Algeria - (and 95 more...)
|
|
| 37 |
NCT01344889 |
Completed |
An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C) |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Correlation between baseline patient characteristics and safety related dose reductions/treatment discontinuations of the long-acting interferon or ribavirin
- Correlation between safety related dose reductions/treatment discontinuations and sustained virological response (SVR: defined as HCV RNA <50 IU/mL at 24 weeks after completion of treatment)
- Correlation of on-treatment factors and dose reduction/treatment discontinuation
- (and 3 more...)
|
4459 |
All |
18 Years and older (Adult, Older Adult) |
NCT01344889 |
MV22255 |
|
October 2009 |
June 2013 |
June 2013 |
April 29, 2011 |
November 2, 2016 |
|
- Elbasan, Albania
- Tirana, Albania
- Algiers, Algeria
- (and 258 more...)
|
|
| 38 |
NCT00875810 |
Completed
Has Results |
PRESTIGE Observational Study |
- Degenerative Cervical Disc Disease
|
|
Observational
|
|
- Medtronic Spinal and Biologics
|
Industry |
- Time Perspective: Prospective
|
- EQ-5D
- Neck Disability Index (NDI) Score
- Duration of Pain Prior to Enrollment
- Intervertebral Disc Space
|
194 |
All |
18 Years and older (Adult, Older Adult) |
NCT00875810 |
PRESTIGE Observational Study |
|
April 2008 |
November 2013 |
November 2013 |
April 3, 2009 |
January 28, 2016 |
March 17, 2015 |
- Hospital Plzen - Lochotin
Plzen, Czech Republic - Hospital Plzen - Lochotin
Plzen, Czech Republic - University Clinic Motol
Prague, Czech Republic - (and 24 more...)
|
|
| 39 |
NCT03387722 |
Recruiting |
Assessment of Treatment Patterns of Severe Asthmatic Patients Across the Gulf Region - SevEos Study |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Asthma treatment and its patterns through generic names.
- Asthma treatment and its patterns through dosage
- Asthma Control
- (and 9 more...)
|
250 |
All |
12 Years and older (Child, Adult, Older Adult) |
NCT03387722 |
D2287R00124 |
SevEos |
December 31, 2017 |
December 31, 2018 |
December 31, 2018 |
January 2, 2018 |
October 10, 2018 |
|
- Mubarak Al Kabeer Hospital
Kuwait, Kuwait - Rashed Allergy Center
Kuwait, Kuwait - Royal Hospital
Muscat, Oman - (and 5 more...)
|
|
| 40 |
NCT03006198 |
Active, not recruiting |
Tracking Biologics Along the Silk Road |
- Arthritis, Rheumatoid; Spondylitis, Ankylosing; Arthritis, Psoriatic; Colitis, Ulcerative
|
|
Observational
|
|
- Janssen Pharmaceutica N.V., Belgium
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Response
- Percentage of Participants Achieving American College of Rheumatology (ACR) 50 Response
- Percentage of Participants Achieving American College of Rheumatology (ACR) 70 Response
- (and 9 more...)
|
140 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03006198 |
CR106936
C0168ARA4017 |
HARIR |
February 4, 2016 |
December 1, 2019 |
December 1, 2019 |
December 30, 2016 |
October 4, 2018 |
|
- Alger, Algeria
- Alexandria, Egypt
- Cairo, Egypt
- (and 5 more...)
|
|
| 41 |
NCT00407537 |
Completed
Has Results |
Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors |
- Hypertension
- Hypercholesterolemia
|
- Drug: Amlodipine besylate/atorvastatin calcium single pill combination
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Framingham 10-year Risk of Total Coronary Heart Disease (CHD) at Month 12
- Framingham 10-year Risk of Total CHD at Month 4
- European Systematic COronary Risk Evaluation (SCORE) 10-year Risk of Fatal Cardiovascular Disease (CVD) at Month 12
- (and 19 more...)
|
1531 |
All |
35 Years to 79 Years (Adult, Older Adult) |
NCT00407537 |
A3841047 |
CRUCIAL |
March 2007 |
October 2009 |
October 2009 |
December 5, 2006 |
July 23, 2015 |
November 11, 2011 |
- Pfizer Investigational Site
Desamparados, San Jose, Costa Rica - Pfizer Investigational Site
Heredia, Costa Rica - Pfizer Investigational Site
San Jose, Costa Rica - (and 123 more...)
|
|
| 42 |
NCT00944424 |
Unknown † |
Phase III Trial of High Dose vs. Standard Dose Vit D2 With Docetaxel in Met Breast ca |
|
- Drug: Docetaxel + High dose Vitamin D2
- Drug: Docetaxel + Standard dose Vitamin D2
|
Interventional
|
Phase 3 |
- King Faisal Specialist Hospital & Research Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Time to progression is from the start of Docetaxel to disease progression. Patients who have not progressed at the time of study completion or who are lost to follow-up are censored at the last Vitamin D administration date.
- Overall survival is defined as the time from start of Docetaxel to death due to any cause. Patients for whom no death is captured on the clinical database are censored at the last date they were known to be alive.
|
260 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00944424 |
RAC # 2091-009 |
GORG-002 |
July 2009 |
July 2012 |
July 2012 |
July 23, 2009 |
December 13, 2011 |
|
- Kuwait Cancer Center
Kuwait City, Kuwait - King Faisal Specialist Hospital & Research Center
Riyadh, Central, Saudi Arabia - King Abdulaziz Hospital and Oncology Center
Jeddah, Saudi Arabia - (and 3 more...)
|
|
| 43 |
NCT02737657 |
Completed |
An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan |
- Diabetes Mellitus, Type 2
|
|
Observational
|
|
- Janssen-Cilag International NV
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of Participants With at Least one Episode of Hypoglycaemia
- Number of Participants With Volume Depletion Events
- Treatment Adherence Based on the Percentage of Prescribed Doses of Canagliflozin or Sulphonylurea Taken by Participants
- (and 9 more...)
|
379 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02737657 |
CR108100
28431754DIA4016 |
CRATOS |
April 2016 |
September 2016 |
September 2016 |
April 14, 2016 |
November 15, 2016 |
|
- Kuwait City, Kuwait
- Amioun, Lebanon
- Beirut, Lebanon
- (and 6 more...)
|
|
| 44 |
NCT01770834 |
Completed |
A Prospective, Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Safety: Incidence of adverse events
- Percentage of patients achieving a clinically meaningful improvement in disease activity: DAS28 reduction of at least 1.2 units, low disease activity (DAS28 </= 3.2) or remission (DAS28 <2.6)
- Clinical/demographic patient characteristics at initiation of RoActemra/Actemra treatment
- Treatment regimens: Concomitant medications
|
100 |
All |
21 Years and older (Adult, Older Adult) |
NCT01770834 |
ML25533 |
|
April 18, 2013 |
January 25, 2017 |
January 25, 2017 |
January 18, 2013 |
March 2, 2018 |
|
- Safat, Kuwait
- Beirut, Lebanon
- Beirut, Lebanon
- (and 9 more...)
|
|
| 45 |
NCT02273856 |
Terminated |
Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL) |
- Indolent Non Hodgkin's Lymphoma (iNHL)
- Chronic Lymphocytic Leukaemia (CLL)
|
|
Observational
|
|
- Astellas Pharma International B.V.
- Astellas Pharma Inc
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Proportion of patients on different types of pharmacological regimen for treatment of Chronic Lymphocytic Leukaemia (CLL) or Indolent Non Hodgkin's Lymphoma (iNHL)
- Duration of response
- Overall survival
- (and 13 more...)
|
25 |
All |
18 Years and older (Adult, Older Adult) |
NCT02273856 |
ONC-MA-1002 |
NADIR |
January 2015 |
August 2015 |
August 2015 |
October 24, 2014 |
June 21, 2016 |
|
- Site JO96201 King Abdullah University Hospital
Irbid, Jordan - Site KW96501 Kuwait Cancer Control Center
Shuwaikh, Kuwait - Site Hammoud Hospital University Medical Center
Beirut, Lebanon - (and 5 more...)
|
|
| 46 |
NCT03161912 |
Recruiting |
A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease |
|
- Drug: Aflibercept (Eylea, BAY86-5321)
|
Observational
|
|
- Bayer
- Regeneron Pharmaceuticals
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Mean change of visual acuity (VA) from baseline to 12 months as evaluated in routine clinical practice per cohort and per country.
- Mean change of visual acuity from baseline to 6, 12 and 24 months after first treatment
- Number of study eyes with pre-determined VA gains and losses (equivalent to 5, 10 and 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters) closest to the visit 6, 12 and 24 months after first treatment
- (and 9 more...)
|
3010 |
All |
18 Years and older (Adult, Older Adult) |
NCT03161912 |
19157 |
AURIGA |
November 24, 2017 |
June 30, 2020 |
September 1, 2020 |
May 22, 2017 |
September 28, 2018 |
|
- Many Locations
Multiple Locations, Egypt - Many Locations
Multiple Locations, France - Many Locations
Multiple Locations, Germany - (and 7 more...)
|
|
| 47 |
NCT03484065 |
Recruiting |
Quality of Life in Patients With Congenital Afibrinogenemia |
- Afibrinogenemia, Congenital
|
- Other: Questionnaire quality of life
|
Observational
|
|
- University Hospital, Geneva
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- The influence of the afibrinogenemia on the patients' quality of life assessed by the Haemo-QoL SF questionnaire (for children) and the Haem-A-QoL questionnaire (for adult)
- Impact of the afibrinogenemic patient's clinical phenotype on the patients' quality of life
|
150 |
All |
8 Years and older (Child, Adult, Older Adult) |
NCT03484065 |
2016-00447 |
QualyAFIB |
June 2016 |
December 2018 |
December 2018 |
March 30, 2018 |
March 30, 2018 |
|
- Children's Hospital of Orange Count
Orange, California, United States - Cohen Children's Medical Center
New Hyde Park, New York, United States - Béni Messous
Algier, Algeria - (and 25 more...)
|
|
| 48 |
NCT03362463 |
Active, not recruiting |
Long-Term Follow-Up and Management Patterns of Patients With Acute Coronary Syndrome in Middle East and Africa |
|
- Other: Non-Interventional Study
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Antithrombotic includinhg Dual Antiplatelet(DAPT) Treatment patterns
- Antihypertensive as apart of ACS Treatment patterns
- Diabetic lowering agents as a part of ACS Treatment patterns in the ACS patients with Diabetes including Type 2 DM
- (and 3 more...)
|
1191 |
All |
Child, Adult, Older Adult |
NCT03362463 |
D1843R00256 |
TOURACO |
December 28, 2015 |
December 31, 2019 |
December 31, 2019 |
December 5, 2017 |
September 12, 2018 |
|
- Research Site
Algiers, Algeria - Research Site
Annaba, Algeria - Research Site
Constantine, Algeria - (and 17 more...)
|
|
| 49 |
NCT03085810 |
Recruiting |
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) |
- Multiple Sclerosis, Relapsing-Remitting
|
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to Onset of Confirmed Disability Progression (CDP) Sustained for at Least 24 and 48 Weeks, As Measured Using Expanded Disability Status Scale (EDSS)
- Percentage of Participants With Confirmed Disability Improvement (CDI) at Year 1, As Measured Using EDSS
- Percentage of Participants With CDP Sustained for At Least 24 and 48 Weeks at Year 1, As Measured Using EDSS
- (and 38 more...)
|
600 |
All |
18 Years to 55 Years (Adult) |
NCT03085810 |
MA30143
2016-002937-31 |
|
March 24, 2017 |
February 25, 2023 |
February 25, 2023 |
March 21, 2017 |
October 12, 2018 |
|
- Center for Neurosciences
Tucson, Arizona, United States - University of California Irvine
Irvine, California, United States - Palo Alto Medical Foundation Research Center
Sunnyvale, California, United States - (and 231 more...)
|
|
| 50 |
NCT02941367 |
Completed |
Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan |
- Diabetes Mellitus, Type 2
|
- Drug: Lixisenatide (AVE0010)
- Drug: Sulfonylurea
- Drug: metformin
- Drug: basal insulin
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of patients with at least 1 documented symptomatic hypoglycemia event (plasma glucose ≤70 mg/dL; 3.9 mmol/L)
- Mean change in HbA1c
- Mean change in body weight
- (and 4 more...)
|
184 |
All |
18 Years and older (Adult, Older Adult) |
NCT02941367 |
LPS14410
U1111-1172-3026 |
LixiRam |
February 23, 2017 |
August 4, 2017 |
August 4, 2017 |
October 21, 2016 |
September 21, 2017 |
|
- Investigational Site Number 356005
Ahmedabad, India - Investigational Site Number 356002
Bangalore, India - Investigational Site Number 356015
Bangalore, India - (and 13 more...)
|
|
| 51 |
NCT02921035 |
Active, not recruiting |
Non-interventional Study to Assess Adherence to Treatment for Patients With Relapsing Multiple Sclerosis |
- Relapsing Multiple Sclerosis
|
- Drug: Rebif (Interferon beta-1a)
|
Observational
|
|
- Merck KGaA
- Merck Serono Middle East FZ LLC
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage adherence of subjects on Rebif, using the Morisky medication adherence scale (MMAS)-4 score
- Percentage of subjects on Rebif who discontinued the treatment
- Time to treatment discontinuation
- (and 5 more...)
|
594 |
All |
18 Years to 60 Years (Adult) |
NCT02921035 |
MS200136_0035 |
MAIN-MS |
June 30, 2016 |
June 30, 2018 |
June 30, 2020 |
September 30, 2016 |
July 25, 2018 |
|
- Research site
Alger, Algeria - Research site
Annaba, Algeria - Research site
Blida, Algeria - (and 38 more...)
|
|
| 52 |
NCT02788214 |
Recruiting |
Helicobacter Pylori Genome Project |
- Gastric Cancer
- Non-Atrophic Gastritis
- Intestinal Metaplasia
|
|
Observational
|
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
|
2000 |
All |
35 Years to 70 Years (Adult, Older Adult) |
NCT02788214 |
999916120
16-C-N120 |
|
May 28, 2016 |
December 31, 2018 |
September 30, 2020 |
June 2, 2016 |
August 9, 2018 |
|
- Arctic Investigations Program, CDC
Anchorage, Alaska, United States - White River Medical Center
Batesville, Arkansas, United States - Vanderbilt University Medical Center
Nashville, Tennessee, United States - (and 39 more...)
|
|
| 53 |
NCT02752737 |
Recruiting |
Cryo AF Global Registry |
|
|
Observational
|
|
- Medtronic Cardiac Rhythm and Heart Failure
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Freedom from Atrial Fibrillation (AF) Recurrence at 12 Months
- Freedom from Atrial Arrhythmia at 12 Months
- Freedom from Device / Procedure Related Adverse Events
|
3000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02752737 |
Cryo AF Global Registry |
|
May 2016 |
December 2022 |
December 2024 |
April 27, 2016 |
September 26, 2018 |
|
- Institituo Cardiovascular Buenos Aires (ICBA)
Buenos Aires, Argentina - Hospital Universitario Fundación Favaloro
Buenos Aires, Argentina - Kepler Universitätsklinikum Med Campus III.
Linz, Austria - (and 56 more...)
|
|
| 54 |
NCT02642159 |
Completed
Has Results |
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia) |
|
- Drug: Alirocumab
- Drug: Statins
- Drug: Ezetimibe
- (and 4 more...)
|
Interventional
|
Phase 4 |
- Sanofi
- Regeneron Pharmaceuticals
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percent Change From Baseline in Non-HDL-C at Week 24: Overall Intent-to-treat (ITT) Analysis
- Percent Change From Baseline in Non-HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
- Percent Change From Baseline in Measured Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24: Overall ITT Analysis
- (and 20 more...)
|
413 |
All |
18 Years and older (Adult, Older Adult) |
NCT02642159 |
LPS14354
2015-001934-19
U1111-1172-5262 |
|
March 15, 2016 |
March 22, 2017 |
May 15, 2017 |
December 30, 2015 |
May 1, 2018 |
May 1, 2018 |
- Investigational Site Number 840-163
Little Rock, Arkansas, United States - Investigational Site Number 840-141
Fresno, California, United States - Investigational Site Number 840-152
Huntington Beach, California, United States - (and 116 more...)
|
|
| 55 |
NCT02555215 |
Active, not recruiting |
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) |
- Multiple Sclerosis, Relapsing-Remitting
|
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The number of participants that experience adverse events (AEs) and serious adverse events (SAEs).
- The number of participants that discontinue study treatment due to an AE.
- The total number of new or newly enlarging T2 hyperintense lesions on brain magnetic resonance imaging (MRI) scans.
- (and 3 more...)
|
20 |
All |
10 Years to 17 Years (Child) |
NCT02555215 |
109MS311
2015-003282-29 |
|
February 22, 2016 |
August 31, 2018 |
August 31, 2018 |
September 21, 2015 |
July 30, 2018 |
|
- Research Site
San Bernardino, California, United States - Research Site
Ghent, Belgium - Research Site
Sofia, Bulgaria - (and 9 more...)
|
|
| 56 |
NCT02536118 |
Recruiting |
Micra Transcatheter Pacing System Post-Approval Registry |
|
- Device: Micra Transcatheter Pacing System
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Acute complication rate
- Long-term complication free survival
- Pacing impedance (ohms) and pacing threshold (volts)
- (and 4 more...)
|
3100 |
All |
Child, Adult, Older Adult |
NCT02536118 |
Micra Registry |
|
July 2015 |
August 2026 |
August 2026 |
August 31, 2015 |
January 23, 2018 |
|
- Birmingham, Alabama, United States
- Los Angeles, California, United States
- Redwood City, California, United States
- (and 153 more...)
|
|
| 57 |
NCT02525874 |
Completed |
Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). |
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis
|
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in lymphocyte subset counts during the first year of treatment.
- Changes in ALCs during the first year of treatment.
- Changes in immunoglobulin G (IgG) isotypes during the first year of treatment.
|
218 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02525874 |
109MS310
2015-001973-42 |
|
August 31, 2015 |
April 23, 2018 |
April 23, 2018 |
August 18, 2015 |
May 18, 2018 |
|
- Research Site
Gilbert, Arizona, United States - Research Site
Long Beach, California, United States - Research Site
Ocala, Florida, United States - (and 31 more...)
|
|
| 58 |
NCT02410200 |
Completed
Has Results |
Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS |
- Multiple Sclerosis, Relapsing-Remitting
|
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in the Number of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans From the Baseline Period to On-Treatment Assessment Period
- Maximum Observed Plasma Concentration (Cmax)
- Time to Reach Maximum Observed Plasma Concentration (Tmax)
- (and 5 more...)
|
22 |
All |
10 Years to 17 Years (Child) |
NCT02410200 |
109MS202
2014-005003-24 |
FOCUS |
September 30, 2015 |
September 23, 2016 |
September 23, 2016 |
April 7, 2015 |
October 23, 2017 |
April 28, 2017 |
- Research Site
San Bernardino, California, United States - Research Site
Gent, Belgium - Research Site
Sofia, Bulgaria - (and 9 more...)
|
|
| 59 |
NCT01595724 |
Completed |
Daily Practice Treatment and Influence of Visanne on the Patient Assessment of Quality of Life |
|
- Drug: Visanne (Dienogest, BAY86-5258)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of patients, who show an improvement of the EHP-5 items
- Mean changes of EHP-5 items by using scores for pre-defined categories
- Baseline demographic characteristics and disease status of patients with endometriosis treated with Visanne
- (and 3 more...)
|
3006 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01595724 |
16108
VS1101 |
DIVA |
May 2012 |
July 2014 |
May 2015 |
May 10, 2012 |
July 10, 2015 |
|
- Many Locations, Belarus
- Many Locations, Egypt
- Many Locations, Jordan
- (and 8 more...)
|
|
| 60 |
NCT02322762 |
Active, not recruiting |
DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings |
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Anti-diabetic treatments prescribed by physicians in a real-world setting.
- Disease control in terms of achieving HbA1c target goals and reducing body weight and blood pressure.
- Changes in anti-diabetic treatments
- (and 4 more...)
|
14173 |
All |
18 Years and older (Adult, Older Adult) |
NCT02322762 |
D1690R00002 |
DISCOVER |
December 30, 2014 |
June 30, 2019 |
June 30, 2019 |
December 23, 2014 |
June 11, 2018 |
|
- Research Site
Alger, Algeria - Research Site
Algiers, Algeria - Research Site
Batna, Algeria - (and 368 more...)
|
|
| 61 |
NCT02283853 |
Recruiting |
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) |
- Relapsing-Remitting Multiple Sclerosis
|
- Drug: dimethyl fumarate
- Drug: Interferon β-1a
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of participants free of new/newly enlarging T2 hyperintense lesions on brain MRI scans
- Number of participants that experience Adverse Events (AEs) or Serious Adverse Events (SAEs)
- Number of participants who discontinue study treatment due to an AE
- (and 10 more...)
|
142 |
All |
10 Years to 17 Years (Child) |
NCT02283853 |
109MS306
2013-002318-11 |
CONNECT |
August 28, 2014 |
September 25, 2020 |
May 30, 2025 |
November 5, 2014 |
September 10, 2018 |
|
- Research Site
Loma Linda, California, United States - Research Site
Boston, Massachusetts, United States - Research Site
Houston, Texas, United States - (and 69 more...)
|
|
| 62 |
NCT02210819 |
Completed |
Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy |
- Deep Vein Thrombosis (DVT) and / or Pulmonary Embolism (PE)
|
- Drug: Rivaroxaban (Xarelto, BAY59-7939)
- Drug: Recommended VTE pharmacological treatments according to international guidelines
|
Observational
|
|
- Bayer
- Janssen Research & Development, LLC
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of major bleedings defined as overt bleeding
- Number of patients with symptomatic recurrent venous thromboembolic events
- All cause mortality
- (and 3 more...)
|
1987 |
All |
18 Years and older (Adult, Older Adult) |
NCT02210819 |
17237
XA1402 |
XALIA LEA |
June 27, 2014 |
November 3, 2016 |
January 20, 2017 |
August 7, 2014 |
March 20, 2018 |
|
- Multiple Locations, Algeria
- Multiple Locations, Egypt
- Multiple Locations, Indonesia
- (and 18 more...)
|
|
| 63 |
NCT01970189 |
Recruiting |
The International ITP Registry |
|
|
Observational
|
|
- South Eastern Sydney Local Health District
- GlaxoSmithKline
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Disease progression of ITP
|
500 |
All |
18 Years and older (Adult, Older Adult) |
NCT01970189 |
CTBR-017 (TRA114972) |
|
January 2011 |
December 2016 |
December 2020 |
October 28, 2013 |
October 27, 2016 |
|
- Canberra Hospital
Canberra, Australian Capital Territory, Australia - St George Hospital
Sydney, New South Wales, Australia - Calvary Mater Newcastle
Sydney, New South Wales, Australia - (and 41 more...)
|
|
| 64 |
NCT01950819 |
Completed |
Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) |
- End Stage Renal Disease (ESRD)
- Chronic Kidney Disease (CKD)
- Hemodialysis
- (and 2 more...)
|
- Biological: Induction therapy
- Drug: Corticosteroids
- Drug: EVR+rCNI
- Drug: MPA+sCNI
|
Interventional
|
Phase 4 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of failure on the composite of treated biopsy-proven acute rejection (tBPAR) or estimated glomerular filtration rate (eGFR) < 50 mL/min/1.73m2.
- Incidence of failure on the composite of (treated biopsy proven acute rejection (tBPAR), graft loss or death
- Incidence of failure on the composite endpoint of tBPAR, graft loss, death or eGFR < 50 mL/min/1.73m2
- (and 17 more...)
|
2037 |
All |
18 Years and older (Adult, Older Adult) |
NCT01950819 |
CRAD001A2433
2013-000322-66 |
TRANSFORM |
December 3, 2013 |
February 1, 2017 |
January 17, 2018 |
September 26, 2013 |
September 26, 2018 |
|
- Novartis Investigative Site
Birmingham, Alabama, United States - Novartis Investigative Site
Loma Linda, California, United States - Novartis Investigative Site
Los Angeles, California, United States - (and 181 more...)
|
|
| 65 |
NCT01758380 |
Completed |
Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan |
|
- Drug: Vildagliptin
- Drug: Gliclazide
- Drug: Metformin
- (and 2 more...)
|
Interventional
|
Phase 4 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of patients experiencing at least one Hypoglycaemic Event (HE) during the Ramadan fasting period to test superiority
- Percentage of patients without an increase in HbA1c (≤ 0.3%) and with no Hypoglycaemic Events (HEs)
- Change from baseline to endpoint in glycosylated hemoglobin (HbA1c)
- (and 8 more...)
|
557 |
All |
18 Years and older (Adult, Older Adult) |
NCT01758380 |
CLAF237A2411
2011-005499-41 |
STEADFAST |
January 2013 |
September 2013 |
September 2013 |
January 1, 2013 |
October 17, 2013 |
|
- Novartis Investigative Site
Frederiksberg, Denmark - Novartis Investigative Site
Alexandria, Egypt - Novartis Investigative Site
Cairo, Egypt - (and 65 more...)
|
|
| 66 |
NCT01675427 |
Completed
Has Results |
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C |
|
- Other: Interleukin 28B testing
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Number of Participants With Interleukin 28B (IL28B) Genotype rs12979860 by Cirrhosis Status and Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Genotype: Treatment-Naive
- Number of Participants With IL28B Genotype rs12979860 by Cirrhosis Status and HCV RNA Genotype: Treatment-Experienced
- Number of Participants With IL28B Genotype rs8099917 by Cirrhosis Status and HCV RNA Genotype: Treatment-Naive
- (and 91 more...)
|
4766 |
All |
18 Years and older (Adult, Older Adult) |
NCT01675427 |
MV25600 |
|
August 2011 |
October 2013 |
October 2013 |
August 30, 2012 |
August 26, 2015 |
June 8, 2015 |
- Alexandria, Virginia, United States
- Buenos Aires, Argentina
- Mar del Plata, Argentina
- (and 207 more...)
|
|
| 67 |
NCT01554618 |
Recruiting |
Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes |
- Children and Adolescent With Type 2 Diabetes
|
- Drug: Exenatide Once Weekly
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Assess effect of EQW on glycemic control
- Safety and tolerability of EQW vs placebo
- Compare effects of EQW vs Placebo
- (and 3 more...)
|
92 |
All |
10 Years to 17 Years (Child) |
NCT01554618 |
D5551C00002 |
|
May 12, 2016 |
June 22, 2020 |
June 29, 2023 |
March 15, 2012 |
October 9, 2018 |
|
- Research Site
Bell Gardens, California, United States - Research Site
Pacific Palisades, California, United States - Research Site
Aurora, Colorado, United States - (and 41 more...)
|
|
| 68 |
NCT01524276 |
Recruiting |
Product Surveillance Registry |
- Cardiac Rhythm Disorders
- Sacral Neuromodulation
- Neurological Disorders
- (and 2 more...)
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Safety and Effectiveness of Market Released products
|
90000 |
All |
Child, Adult, Older Adult |
NCT01524276 |
PSR |
PSR |
January 2012 |
January 2030 |
January 2030 |
February 1, 2012 |
September 21, 2018 |
|
- Birmingham, Alabama, United States
- Anchorage, Alaska, United States
- Chandler, Arizona, United States
- (and 252 more...)
|
|
| 69 |
NCT00868153 |
Completed |
Mirena in Idiopathic Menorrhagia |
|
- Drug: Levonorgestrel IUS (Mirena , BAY86-5028)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To evaluate the improvement in the quality of life and the degree of satisfaction of women with idiopathic menorrhagia treated with Mirena
- Information about the pattern of menstrual bleeding recorded in an ongoing way throughout the duration of the study
- The health-related quality of life questionnaire SF-36 at Visits 1 and 4
- (and 3 more...)
|
1125 |
Female |
30 Years to 45 Years (Adult) |
NCT00868153 |
14494
MA0501 |
|
August 2004 |
November 2008 |
November 2008 |
March 24, 2009 |
February 18, 2015 |
|
- Many Locations, Bulgaria
- Many Locations, Croatia
- Many Locations, India
- (and 10 more...)
|
|
| 70 |
NCT01447446 |
Completed
Has Results |
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C |
|
- Drug: Peg-IFN Alfa-2a
- Drug: Peg-IFN Alfa-2b
- Drug: Ribavirin
- (and 2 more...)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of Participants With Sustained Virological Response at 24 Weeks Post Completion of the Treatment Period (SVR24)
- Percentage of Participants With Sustained Virological Response at 12 Weeks Post Completion of the Treatment Period (SVR12)
- Virological Response at Various on Treatment Time Points and End of Treatment (EOT)
- (and 11 more...)
|
4442 |
All |
18 Years and older (Adult, Older Adult) |
NCT01447446 |
MV25599 |
|
September 2011 |
July 2015 |
July 2015 |
October 6, 2011 |
March 30, 2017 |
March 30, 2017 |
- Antwerpen, Belgium
- Antwerpen, Belgium
- Bouge, Belgium
- (and 269 more...)
|
|
| 71 |
NCT01089023 |
Completed
Has Results |
A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis |
|
- Drug: tocilizumab [RoActemra/Actemra]
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants Reporting Any Adverse Event - Overall Summary of Events
- Percentage of Participants by Disease Activity Score Based on 28-Joint Count (DAS28) Category
- Percentage of Participants Achieving a Clinically Meaningful Improvement as Measured by DAS28
- (and 6 more...)
|
95 |
All |
18 Years and older (Adult, Older Adult) |
NCT01089023 |
ML22440 |
|
January 2010 |
December 2011 |
December 2011 |
March 18, 2010 |
July 22, 2014 |
July 22, 2014 |
- Manama, Bahrain
- Riffa, Bahrain
- Isfahan, Iran, Islamic Republic of
- (and 6 more...)
|
|
| 72 |
NCT01239732 |
Completed
Has Results |
A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer |
|
- Drug: Paclitaxel
- Drug: Bevacizumab
- Drug: Carboplatin
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With at Least One Adverse Event (AE)
- Progression-Free Survival (PFS)
- Percentage of Participants Achieving Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST Version 1.0
- (and 5 more...)
|
1021 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01239732 |
MO22923
2010-019525-34 |
|
December 2010 |
March 2015 |
March 2015 |
November 11, 2010 |
June 10, 2016 |
June 10, 2016 |
- Buenos Aires, Argentina
- Buenos Aires, Argentina
- Buenos Aires, Argentina
- (and 239 more...)
|
|
| 73 |
NCT01204593 |
Completed |
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus |
- Diabetes Mellitus, Type 1
|
- Drug: INSULIN GLARGINE
- Drug: INSULIN GLULISINE
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in hemoglobin A1c (HbA1c) values (following the reference of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC))
- Change of HbA1c
- Percentage of patients with HbA1c < 7%
- (and 5 more...)
|
206 |
All |
18 Years to 60 Years (Adult) |
NCT01204593 |
LANTU_R_05033
U1111-1116-3450 |
SUBSTITUTE |
November 2010 |
January 2013 |
January 2013 |
September 17, 2010 |
March 17, 2014 |
|
- Investigational Site Number 01201
Algeries, Algeria - Investigational Site Number 01202
Algiers, Algeria - Investigational Site Number 01203
Algiers, Algeria - (and 40 more...)
|
|
| 74 |
NCT01121835 |
Completed |
Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study |
- Diabetes Mellitus, Type 2
|
- Drug: INSULIN GLARGINE
- Drug: INSULIN GLULISINE
- Drug: PREMIXED INSULIN
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of patients with Glycosylated Haemoglobin (HbA1c) <7% with no documented symptomatic hypoglycemia (confirmed by a Plasma Glucose (PG) ≤ 56 mg/dL [3.1 mmol/L]
- 7-point plasma glucose (PG) profile recorded on 3 consecutive days
- Self-monitored PG (Plasma Glucose) values over 3 consecutive days
- (and 3 more...)
|
934 |
All |
35 Years and older (Adult, Older Adult) |
NCT01121835 |
LANTU_C_04589
2009-018172-33
U1111-1116-9859 |
GALAPAGOS |
February 2010 |
March 2012 |
March 2012 |
May 12, 2010 |
April 4, 2013 |
|
- Investigational Site Number 040-004
Sankt Stefan, Austria - Investigational Site Number 040-002
Vienna, Austria - Investigational Site Number 040-001
Vienna, Austria - (and 93 more...)
|
|
| 75 |
NCT00968708 |
Completed
Has Results |
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome |
- Diabetes Mellitus, Type 2
- Acute Coronary Syndrome
|
- Drug: Alogliptin
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of Participants With Primary Major Adverse Cardiac Events (MACE)
- Percentage of Participants With Secondary Major Adverse Cardiac Events (MACE)
|
5380 |
All |
18 Years and older (Adult, Older Adult) |
NCT00968708 |
SYR-322_402
U1111-1111-6825
2009-011222-34
JapicCTI-101246
DOH-27-0310-3047
09/H0709/63
CTRI/2010/091/000046
NMRR-09-872-4471 |
EXAMINE |
September 2009 |
April 2013 |
June 2013 |
August 31, 2009 |
May 2, 2014 |
April 15, 2014 |
- Birmingham, Alabama, United States
- Dothan, Alabama, United States
- Mobile, Alabama, United States
- (and 915 more...)
|
|
| 76 |
NCT00949442 |
Completed |
Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment |
- Diabetes Mellitus, Type 2
|
- Drug: Insulin Glargine (HOE901) [Lantus]
- Drug: Glimepiride
- Drug: human insulin [NPH]
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- HbA1c
- Self-monitored fasting plasma glucose (FPG)
- 8-points profiles
- (and 3 more...)
|
708 |
All |
30 Years to 70 Years (Adult, Older Adult) |
NCT00949442 |
LANTU_C_02762
EUDRACT #: 2007-006640-22 |
LANCELOT |
July 2009 |
July 2012 |
July 2012 |
July 30, 2009 |
August 21, 2012 |
|
- Investigational Site Number 076-001
Fortaleza, Brazil - Investigational Site Number 076-006
Fortaleza, Brazil - Investigational Site Number 076-005
Porto Alegre, Brazil - (and 84 more...)
|
|
| 77 |
NCT00930488 |
Completed |
Treatment of Patients With Acute Sinusitis |
- Acute Bacterial Sinusitis
|
- Drug: Avelox (Moxifloxacin, BAY12-8039)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Evaluation of potential benefits of an antibacterial therapy with Avelox® (moxifloxacin) in patients with acute bacterial sinusitis to whom this treatment was prescribed. Especially the time to improvement and resolution of clinical signs and symptoms of
- Evaluation of tolerability and safety of Avalox® in daily practice were investigated.
- Patient characteristics in acute bacterial sinusitis
- (and 2 more...)
|
6777 |
All |
Child, Adult, Older Adult |
NCT00930488 |
12803
TOPAS
AX 0601
12867 - AX0601AT
12868 - AX0601PK
12869 - AX0601EG
12870 - AX0601NL
12973 - AX0601SK
12974 - AX0601SG
13026 - AX0601ID
13046 - AX0601PH
13111 - AX0601RO
13065 - AX0601CN
13207 - AX0601FR
13166 - AX0601MY |
|
March 2007 |
December 2008 |
December 2008 |
June 30, 2009 |
November 20, 2012 |
|
- Many Locations, Austria
- Many Locations, Bahrain
- Many Locations, China
- (and 16 more...)
|
|
| 78 |
NCT00905684 |
Completed |
Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC) |
|
- Drug: EE30/DRSP (Yasmin, BAY86-5131)
- Drug: Any other OC
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Analyses of continuation rates and compliance stratified by the subject's knowledge on the respective topics and time spent for counseling.
- Analyses stratified by baseline factors such as age group, presence or absence of cycle disorders, and history of oral contraceptive method will be performed as well.
- Special attention will be paid to serious adverse events and unexpected or unlisted ADRs.
|
5446 |
Female |
18 Years and older (Adult, Older Adult) |
NCT00905684 |
14565
YA0801 |
|
June 2009 |
|
December 2011 |
May 20, 2009 |
March 7, 2012 |
|
- Many locations, Albania
- Many Locations, Bahrain
- Many locations, Egypt
- (and 10 more...)
|
|
| 79 |
NCT00882453 |
Completed |
Physical Activity and Fatigue in Early Multiple Sclerosis (MS) |
|
- Drug: Interferon beta-1b (Betaseron, BAY86-5046)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Physical Activity and Fatigue
- Health-related Quality of Life
- Depression
|
1739 |
All |
18 Years and older (Adult, Older Adult) |
NCT00882453 |
13853
BF0601
310721 |
BEGIN |
August 2006 |
March 2011 |
March 2011 |
April 16, 2009 |
May 30, 2012 |
|
- Many Locations, Australia
- Many Locations, Austria
- Many Locations, Bahrain
- (and 30 more...)
|
|
| 80 |
NCT00874926 |
Completed |
EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS |
|
- Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Efficacy and Safety of Kogenate Bayer/FS
|
405 |
Male |
Child, Adult, Older Adult |
NCT00874926 |
13405
KG0702 |
|
June 2008 |
November 2012 |
April 2013 |
April 3, 2009 |
January 29, 2014 |
|
- Many Locations, Bahrain
- Many Locations, Bosnia and Herzegovina
- Many Locations, Croatia
- (and 14 more...)
|
|
| 81 |
NCT00787657 |
Completed |
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment |
- Relapsing Remitting Multiple Sclerosis (RRMS)
|
- Drug: Interferon beta-1b (Betaseron, BAY86-5046)
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Proportion of patients adhering to treatment
- Rate of early treatment termination
- Rate of study dropout
- (and 6 more...)
|
1723 |
All |
12 Years and older (Child, Adult, Older Adult) |
NCT00787657 |
13852
311941
BF0703 |
BEACON |
June 2008 |
September 2013 |
October 2014 |
November 7, 2008 |
October 16, 2015 |
|
- Many Locations, Argentina
- Many Locations, Bahrain
- Many Locations, Belgium
- (and 33 more...)
|
|
| 82 |
NCT00382525 |
Completed |
PANORAMA Observational Study |
- Arrhythmia
- Sinus Node Disease
- Heart Failure
- Heart Block
|
- Device: Cardiac Rhythm Management device
|
Observational
|
|
- Medtronic Bakken Research Center
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To construct a computerized database of national profiles and epidemiological data on patients wearing Medtronic Cardiac Rhythm Management Devices
|
8586 |
All |
Child, Adult, Older Adult |
NCT00382525 |
Version 1 April 25th, 2005 |
|
January 2005 |
October 2012 |
March 2013 |
September 29, 2006 |
September 6, 2017 |
|
- C.H.I.R.E.C. - Site de Braine la Alleud
Braine l'Alleud, Belgium - A.Z. Klina
Brasschaat, Belgium - St. Vincentius-Campus St. Jozef
Mortsel, Belgium - (and 24 more...)
|
|
| 83 |
NCT00271180 |
Recruiting |
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products |
- Arrhythmia
- Bradycardia
- Heart Failure
- Sinus Tachycardia
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Lead related complications for each lead model.
|
13000 |
All |
Child, Adult, Older Adult |
NCT00271180 |
602 |
PPR |
January 1983 |
December 2024 |
December 2024 |
December 30, 2005 |
December 2, 2017 |
|
- Birmingham, Alabama, United States
- Anchorage, Alaska, United States
- Gilbert, Arizona, United States
- (and 218 more...)
|
|
| 84 |
NCT00242567 |
Completed
Has Results |
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer |
|
- Drug: Zoledronic Acid
- Drug: Androgen Deprivation Therapy (ADT)
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Skeletal-related Event-free Survival in Men With Bone Metastases From Prostate Cancer
- Overall Survival at 18 Months and 3 Years
- Time to Occurrence of Skeletal Related Event or Death
- Skeletal-related Event(SRE)-Free Survival
|
522 |
Male |
18 Years and older (Adult, Older Adult) |
NCT00242567 |
CZOL446E2432 |
|
December 2005 |
January 2012 |
January 2012 |
October 20, 2005 |
May 7, 2014 |
March 6, 2013 |
- Novartis Investigative Site
Adelaide, Australia - Novartis Investigative Site
Brisbane, Australia - Novartis Investigative Site
Melbourne, Australia - (and 24 more...)
|
|
| 85 |
NCT00196742 |
Recruiting |
Fabry Disease Registry |
|
|
Observational
|
|
- Genzyme, a Sanofi Company
- Sanofi
|
Industry |
- Observational Model: Cohort
- Time Perspective: Other
|
- To evaluate the long-term safety and effectiveness of Fabrazyme®
|
9000 |
All |
Child, Adult, Older Adult |
NCT00196742 |
FABRY REGISTRY
DIREGC07006 |
|
July 31, 2001 |
July 30, 2021 |
July 30, 2021 |
September 20, 2005 |
October 1, 2018 |
|
- Investigational Site Number 840018
Birmingham, Alabama, United States - Investigational Site Number 840073
Birmingham, Alabama, United States - Investigational Site Number 840109
Little Rock, Arkansas, United States - (and 200 more...)
|
|
| 86 |
NCT00144794 |
Recruiting |
Mucopolysaccharidosis I (MPS I) Registry |
- Mucopolysaccharidosis I (MPS I)
|
|
Observational
|
|
- Genzyme, a Sanofi Company
- Sanofi
|
Industry |
- Observational Model: Cohort
- Time Perspective: Other
|
- To evaluate the long-term effectiveness of Aldurazyme
|
1500 |
All |
Child, Adult, Older Adult |
NCT00144794 |
MPS I Registry
DIREGC07008 |
|
November 20, 2003 |
December 31, 2020 |
December 31, 2020 |
September 5, 2005 |
October 11, 2018 |
|
- Investigational Site Number 840109
Little Rock, Arkansas, United States - Investigational Site Number 840108
Los Angeles, California, United States - Investigational Site Number 840042
Sacramento, California, United States - (and 116 more...)
|
|
| 87 |
NCT00143234 |
Completed |
Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels |
- Hypertension
- Hyperlipidemia
|
- Drug: Amlodipine/atorvastatin single pill
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate the efficacy of amlodipine/atorvastatin therapy by assessing the percentage of intent-to-treat subjects achieving both BP and lipid treatment goals (JNC VII and NCEP ATP III)
- To assess changes from baseline in lipid profile and systolic and diastolic BP after 14 weeks treatment; and in this secondary and the primary objectives stratified by prior BP and lipid therapy, and in diabetic subjects; safety
|
1825 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT00143234 |
A3841024 |
GEMINI-AALA |
May 2004 |
|
July 2005 |
September 2, 2005 |
April 22, 2015 |
|
- Pfizer Investigational Site
Buenos Aires, Argentina - Pfizer Investigational Site
Buenos Aires, Argentina - Pfizer Investigational Site
Buenos Aires, Argentina - (and 115 more...)
|
|
| 88 |
NCT00137020 |
Completed |
Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder |
- Schizophrenia
- Psychotic Disorders
|
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary efficacy variable will be change from baseline in Brief Psychiatric Rating Scale (BPRS) total score
- Change From Baseline In Clinical Global Impression Severity (CGI-S)
- Clinical Global Impression Improvement (CGI-I)
- (and 11 more...)
|
294 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00137020 |
A1281117 |
|
November 2004 |
|
April 2006 |
August 29, 2005 |
August 15, 2006 |
|
- Pfizer Investigational Site
Alexandria, Egypt - Pfizer Investigational Site
Assiut, Egypt - Pfizer Investigational Site
Cairo, Egypt - (and 24 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: